Esperion Therapeutics | ESPR - Operating Profit


Esperion Therapeutics reported $-16.03M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Alterity Therapeutics Limited AUD -7.77M 2.99M Jun/2023
Amarin USD -1.7M 8.47M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Cipla INR 9.77B 6.21B Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Esperion Therapeutics USD -16.03M 18.6M Sep/2024
Geron USD -10.79M 3.1M Dec/2025
Grifols EUR 411.56M 15.51M Sep/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Heron Therapeutics USD -5.66M 782K Sep/2024
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Merck USD 6.24B 318M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Moderna USD -857M 597M Dec/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Pfizer USD 4.65B 3.99B Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
United Therapeutics USD -14.6M 403.9M Dec/2025
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024